Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that cannot be surgically removed or you choose not to have surgery.
- Your cancer is at stage 2, 3, or 4 (but only if the spread is to lymph nodes, not distant organs).
- You have not had any prior cancer treatment for this disease and are scheduled to receive chemoradiation.
- You have already had a special genetic test (1021-gene panel) done on your tumor tissue.
- You are between 18 and 80 years old.
- You are in good general health, able to perform daily activities without help (ECOG score 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of chemotherapy, immunotherapy, and radiation for esophageal cancer that cannot be surgically removed. It also uses a simple blood test (ctDNA) to monitor your cancer's response throughout treatment.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
This trial tests whether a personalized treatment plan, chosen using a lab-grown model of your tumor, works better than standard therapy for esophageal cancer that can be surgically removed. It aims to find the most effective drugs for you before surgery.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This study tests a new, more precise type of radiation therapy for esophageal cancer that adjusts the treatment in real time using a special CT scan. It aims to deliver a stronger dose to the tumor while sparing healthy tissue, which could improve outcomes.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.